Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-CHOP for de-novo PTCL with TFH phenotype
ChiCTR2100047467Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, tucidinostat, cyclophosphamide, doxorubicin, vincristine and 1 more in T-cell lymphoma follicular helper (TFHL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 1 more, sponsored by West China Hospital of Sichuan University. Primary endpoint: complete remission rate. Started Jul 2021; status: recruiting.
02
Drugs
azacitidinetucidinostatcyclophosphamidedoxorubicinvincristine
03
Conditions
T-cell lymphoma follicular helper (TFHL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Beyond the preview
Go deeper on ChiCTR2100047467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047467.